Marksans Pharma Gets UK Nod for Oral Solution to Treat Epilepsy

Marksans Pharma on Tuesday announced that it has received approval from the UK health regulator to market an oral solution for controlling certain seizures in treating epilepsy.

 

Key Takeaways from Marksans Pharma:

  • Marksans Pharma gets UK health regulator approval to market an oral solution for controlling certain seizures in treating epilepsy.
  •  Relonchem, a wholly subsidiary of Marksans Pharma has been awarded a marketing authorisation by the MHRA in the UK for Levetiracetam Relonchem Oral Solution, in 100 mg/ml.

 

Marksans Pharma said its wholly owned subsidiary Relonchem has been awarded a marketing authorisation by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom.

 

The authorisation has approved Relonchem’s product, Levetiracetam Relonchem Oral Solution, in 100 mg/ml. This oral solution is used to treat the disease epilepsy.

 

The product will be manufactured at the company’s manufacturing facility located in the UK, the pharmaceutical company stated in the exchange filing.

 

About Marksans Pharma Limited:

Marksans Pharma Limited headquartered in Mumbai is engaged in the research, manufacturing, and marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities are located in India, the USA and the UK and are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company has a robust product portfolio spread across major therapeutic segments of CVS, CNS, Antidiabetic, Pain Management, Gastroenterological and Anti allergies. 

 

Read More About Marksans Pharma Limited Share Price Here!

Related Blogs
blog-logo

Share Market

blog-logo

8 mins read . 19 Jul 2024

Stock Market Trading Time in India

  • 2 people read
blog-logo

Share Market

blog-logo

11 mins read . 19 Jul 2024

How To Trade in T2T Stocks

  • 2 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions